Because the
cholinergic system is down-regulated in the brain of
Alzheimer's disease patients, cognitive deficits in
Alzheimer's disease patients are significantly improved by
rivastigmine treatment. To address the mechanism underlying
rivastigmine-induced memory improvements, we chronically treated olfactory bulbectomized (OBX) mice with
rivastigmine. The chronic
rivastigmine treatments for 12-13 days starting
at 10 days after OBX operation significantly improved memory-related behaviors assessed by Y-maze task, novel object recognition task, passive avoidance task, and Barnes maze task, whereas the single
rivastigmine treatment failed to improve the memory. Consistent with the improved memory-related behaviors, long-term potentiation in the hippocampal CA1 region was markedly restored by
rivastigmine treatments. In immunoblotting analyses, the reductions of
calcium/calmodulin-dependent protein kinase II (
CaMKII) autophosphorylation and
calcium/calmodulin-dependent protein kinase IV (CaMKIV) phosphorylation in the CA1 region in OBX mice were significantly restored by
rivastigmine treatments. In addition, phosphorylation of AMPAR subunit
glutamate receptor 1 (GluA1) (Ser-831) and cAMP-responsive
element-
binding protein (Ser-133) as downstream targets of
CaMKII and CaMKIV, respectively, in the CA1 region was also significantly restored by chronic
rivastigmine treatments. Finally, we confirmed that
rivastigmine-induced improvements of memory-related behaviors and long-term potentiation were not obtained in CaMKIIα(+/-) mice. On the other hand, CaMKIV(-/-) mice did not exhibit the
cognitive impairments. Taken together, the stimulation of
CaMKII activity in the hippocampus is essential for
rivastigmine-induced memory improvement in OBX mice.